NCT01625260View on ClinicalTrials.gov

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 30, 2012

Primary Completion Date

March 8, 2018

Study Completion Date

March 8, 2018

Conditions
Non-muscle Invasive Bladder Cancer
Interventions
BIOLOGICAL

ALT-801

Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 3, 5, 8 and 15 of each course.

DRUG

Gemcitabine

Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 1 and 8 of each course.

Trial Locations (5)

15232

UPMC Cancer Center, Pittsburgh

32806

UF Health Center at Orlando Health, Orlando

35294

University of Alabama Comprehensive Cancer Center, Birmingham

73104

University of Oklahoma Health Science Center, Oklahoma City

95817

University of California Davis, Sacramento

Sponsors

Lead Sponsor

Altor BioScience
All Listed Sponsors
lead

Altor BioScience

INDUSTRY

collaborator

James and Esther King Biomedical Research Program

OTHER